Angioslide

Embolic Capture Angioplasty Devices

Health Tech & Life Sciences
Non Active, Jan 2018 ceased to operate

Company Overview

Snapshot

Founded in March 2005 by Amos Nahir and Eran Hirszowicz, Angioslide operated with 11–50 employees. The company raised $33.15M across 7 funding rounds from 9 investors. A key milestone was the European launch of its 300mm long device in September 2011, designed for treating the entire Superficial Femoral Artery with a single device.

Business overview

Angioslide develops cost-effective products for emboli management during vascular interventions. The company's core product is PROTEUS, an FDA-cleared device that captures and removes embolic particles dislodged during peripheral artery procedures. PROTEUS functions similarly to an angioplasty balloon, incorporating a single-use suction mechanism for debris containment and removal. Angioslide serves the medical devices market within the Health Tech & Life Sciences sector, with its products cleared for lower limb use in the United States and Europe.

Strategic signal

In May 2012, Angioslide announced FDA 510(k) clearance for its PROTEUS Below The Knee device. This clearance was a significant regulatory validation, expanding the device's application and market potential within the critical area of peripheral artery disease treatment, signaling the company's ability to meet stringent medical device standards and address broader patient needs.

Company Intelligence Q&A

What is Angioslide's primary product?
Angioslide's primary product is PROTEUS, an FDA-cleared device designed for embolic capture during vascular interventions in peripheral arteries.
When did Angioslide launch its 300mm device in Europe?
In September 2011, Angioslide announced the European launch of its new 300mm long device, which allows for the treatment of the entire Superficial Femoral Artery with a single device.
When did Angioslide receive FDA clearance for its PROTEUS Below The Knee device?
Angioslide announced FDA 510(k) clearance for its PROTEUS Below The Knee device in May 2012.
Which investors participated in Angioslide's January 2013 financing round?
In January 2013, Angioslide completed a financing round with participation from Triventures and BioStar Capital.
When was Angioslide named one of Israel's top promising startups?
Angioslide was named one of Israel's top ten most promising startups of 2011 in November 2011.

External links